FindTrial
Sign In

Risk factors for adverse reactions in patients with RA caused by JAK inhibitors

Risk factors of adverse reactions in RA patients using JAK inhibitors in Chinese population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069666
Enrollment
Unknown
Registered
2023-03-22
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

RA patients using JAK inhibitors:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Patients aged 18 or above who were admitted to West China Hospital of Sichuan University from May 2020 to May 2022; (2) RA patients who met the ACR/EULAR 2010 classification criteria; (3) Perfect clinical data.

Exclusion criteria

Exclusion criteria: (1) Combined with other autoimmune diseases other than RA; (2) Complicated with severe heart, liver and renal insufficiency, infection and tuberculosis before medication; (3) Complicated with venous thrombosis and malignant tumor before medication.

Design outcomes

Primary

MeasureTime frame
Erythrocyte sedimentation rate (ESR);Rheumatoid factors;C-reactive protein;Anti-cyclic peptide containing citrulline;White blood cell count;Drug dose;—

Secondary

MeasureTime frame
Neutral segmented granulocyte absolute value;Lymphocyte absolute value;—

Countries

China

Contacts

Public ContactYin Geng

West China Hospital of Sichuan University

yingeng1975@163.com13808029911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026